Physician profile
Jeffrey Stern
NPI 1487685228
$2,297.96
in general payments reported to CMS, 2019-2025
15 companies · $91.51 in 2025
The $91.51 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $68.76 · 2021: $88.20 · 2022: $461 · 2023: $532 · 2024: $370 · 2025: $91.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $600.80 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $414.57 | 2019-2024 | Vabysmo |
| Astellas Pharma US INC | $259.42 | 2024-2025 | Izervay |
| Spark Therapeutics, INC. | $246.40 | 2019-2023 | |
| Allergan, INC. | $220.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $133.53 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.15 | 2019 | |
| Xvivo Perfusion INC. | $72.51 | 2022 | |
| Coherus Oncology, INC. | $54.86 | 2022-2023 | |
| Abbvie INC. | $51.90 | 2023-2025 | Ozurdex |
| Eyepoint US, INC. | $44.25 | 2022 | |
| Sandoz INC. | $36.05 | 2024-2025 | Cimerli |
| Biogen, INC. | $29.43 | 2022 | |
| Kala Pharmaceuticals, INC. | $13.09 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.